H
HalioDx
Providing oncologists and biopharma with first-in-class immune-based diagnostic products and services
About HalioDx
HalioDx was founded with a vision to revolutionize the field of precision medicine. The company was established by a team of innovative scientists and entrepreneurs, although specific names of the founders are not readily available. HalioDx focused on developing diagnostic solutions that enable personalized treatment for cancer patients, leveraging the power of immuno-oncology.
Read full description
The company quickly gained recognition for its unique approach to diagnostics, which combined advanced biomarker technologies with a deep understanding of the tumor microenvironment. This allowed HalioDx to provide critical insights into how a patient's immune system interacts with cancer, thus guiding more effective treatment strategies.
A significant milestone in HalioDx's journey was its acquisition by Veracyte in 2021. This acquisition was a strategic move that expanded Veracyte's capabilities in the field of cancer diagnostics, integrating HalioDx's innovative solutions into its portfolio. The merger aimed to accelerate the development and commercialization of advanced diagnostic tests, ultimately improving patient outcomes in oncology.
Through its journey, HalioDx has remained committed to advancing precision medicine, continually pushing the boundaries of what is possible in cancer diagnostics. The company's story is a testament to the impact of innovative science and strategic partnerships in transforming healthcare.
At a glance
- Status
- Acquired
- Founded
- 2014
- Headquarters
- Marseille, France
- Open positions
- None listed
- Dealroom signal
- 58.6/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Testing, Risk Management, Analytics, Predictive Analytics, Biotechnology, Oncology, Spinout, Go Global (EIT Health)
- Technology
- Big Data
- Business model
- Manufacturing
- Client focus
- b2b
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Aug 2021 | $286M | $286M | Veracyte | — |
| SUPPORT PROGRAM✓Other financing | Oct 2019 | $2K | — | EIT Health | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for HalioDx is 550 monthly website visits, up 27.9% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
Turenne Capital
Bpifrance
Quest for Growth- MSMI Care S.A.
BNP Paribas
Sham
Sofipaca
Other known investors3 additional known investors
EIT Health
INSERM
Veracyte
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about HalioDx on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See HalioDx’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.